Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.54 |
| ▸ | TERT | O14746 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | GLI1 | P08151 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494638 | 1.00 | PRCP (0.54) | PRCPTERTHTR2CHTR2BNOS2 | |
| SCHEMBL8789836 | 1.00 | PRCP (0.54) | PRCPTERTHTR2CHTR2BNOS2 | |
| Hydrochloric Acid SCHEMBL7702578 | 0.98 | PRCP (0.53) | PRCPTERTHTR2CHTR2BNOS2 | |
| Hydrochloric Acid SCHEMBL11516357 | 0.98 | PRCP (0.53) | PRCPTERTHTR2CHTR2BNOS2 | |
| Glycine SCHEMBL7541811 | 0.92 | PRCP (0.48) | PRCPTERTHTR2CHTR2BNOS2 | |
| SCHEMBL5959019 | 0.84 | PRCP (0.44) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL620066 | 0.84 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL620067 | 0.84 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL8789170 | 0.84 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL943040 | 0.83 | PRCP (0.58) | PRCPTERTHTR2CHTR2BNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688843-A1 | GNRH-BINDING POLYPEPTIDES AND USES THEREOF | 272Bio Limited (GB) | 2026-02-11 | — | — | EP | claimed |
| US-12521395-B2 | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2026-01-13 | — | — | US | claimed |
| EP-4055015-B1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-04-02 | — | — | EP | claimed |
| WO-2024200846-A1 | GNRH-BINDING POLYPEPTIDES AND USES THEREOF | 272BIO Limited (GB) | 2024-10-03 | — | — | WO | claimed |
| US-20240299511-A1 | AN IMMUNOGEN | UNIVERSITY OF PRETORIA (ZA) | 2024-09-12 | — | — | US | claimed |
| EP-4284419-A1 | AN IMMUNOGEN | University Of Pretoria (ZA) | 2023-12-06 | — | — | EP | claimed |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-01-05 | — | — | US | claimed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | claimed |
| EP-4055015-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2022-09-14 | — | — | EP | claimed |
| WO-2022162539-A1 | AN IMMUNOGEN | UNIVERSITY OF PRETORIA (ZA) | 2022-08-04 | — | — | WO | claimed |
| US-20060217316-A1 | Method for the treatment of prostate cancer | GENIX THERAPEUTICS, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2004087190-A1 | METHOD FOR THE TREATMENT OF PROSTATE CANCER | GENIX THERAPEUTICS INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-4493828-A | Use of thyrotropin releasing hormone and related peptides as poultry growth promotants | MERCK & CO., INC. (US) | 1985-01-15 | — | — | US | claimed |
| US-3953416-A | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same | FOLKERS KARL | 1976-04-27 | — | — | US | claimed |
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4688843-A1 | GNRH-BINDING POLYPEPTIDES AND USES THEREOF | 272Bio Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-3953416-A | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same | FOLKERS KARL | 1976-04-27 | — | — | US | disclosed |
| US-3947569-A | Process for preparing the releasing hormone of luteinizing hormone (LH) and of follicle stimulating hormone (FSH), salts and compositions thereof, and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
| US-3835108-A | PROCESS FOR PREPARING THE RELEASING HORMONE OF LUTEINIZING HORMONE(LH)AND OF FOLLICLE STIMULATING HORMONE(FSH),SALTS AND COMPOSITIONS THEREOF,AND INTERMEDIATES THEREFOR | AMERICAN HOME PROD | 1974-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | TLR8, MYD88, TLR6 | PRCP 1203/4885TERT 3958/4885HTR2C 2860/4885 |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | PRCP 1530/4885TERT 3419/4885HTR2C 254/4885 |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | PRCP 2951/4885TERT 231/4885HTR2C 4190/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | PRCP 3669/4885TERT 3959/4885HTR2C 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.